Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Cash from Operations: 2015-2025

Historic Cash from Operations for Assembly Biosciences (ASMB) over the last 11 years, with Sep 2025 value amounting to -$15.1 million.

  • Assembly Biosciences' Cash from Operations rose 0.73% to -$15.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$55.7 million, marking a year-over-year decrease of 343.00%. This contributed to the annual value of -$51.1 million for FY2024, which is 324.76% down from last year.
  • Assembly Biosciences' Cash from Operations amounted to -$15.1 million in Q3 2025, which was up 9.70% from -$16.8 million recorded in Q2 2025.
  • Over the past 5 years, Assembly Biosciences' Cash from Operations peaked at $73.6 million during Q4 2023, and registered a low of -$33.3 million during Q1 2021.
  • For the 3-year period, Assembly Biosciences' Cash from Operations averaged around -$7.6 million, with its median value being -$15.2 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first plummeted by 277.36% in 2021, then skyrocketed by 482.50% in 2023.
  • Quarterly analysis of 5 years shows Assembly Biosciences' Cash from Operations stood at -$19.4 million in 2021, then increased by 0.56% to -$19.3 million in 2022, then spiked by 482.50% to $73.6 million in 2023, then tumbled by 100.55% to -$407,000 in 2024, then increased by 0.73% to -$15.1 million in 2025.
  • Its Cash from Operations stands at -$15.1 million for Q3 2025, versus -$16.8 million for Q2 2025 and -$23.4 million for Q1 2025.